OVID · Insider Trading
Ovid Therapeutics Inc. Common Stock
Every open-market purchase and sale reported by OVID officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | Charles Ross Carter | Chief Financial Officer | A | +50,000 | — |
| 2026-06-17 | Anna Greka | Director | A | +130,000 deriv. | — |
| 2026-04-09 | Stelios Papadopoulos | Director | A | +17,578 | +$45.00K |
| 2026-04-09 | Bart Friedman | Director | A | +8,789 | +$22.50K |
| 2026-04-09 | Kevin Joseph Fitzgerald | Director | A | +17,578 | +$45.00K |
| 2026-03-25 | Jeremy M Levin | Executive Chairman | M | +47,333 | +$66.27K |
| 2026-03-02 | Jeremy M Levin | Director | A | +957,000 deriv. | — |
| 2026-03-02 | Stelios Papadopoulos | Director | A | +65,000 deriv. | — |
| 2026-03-02 | Barbara Gayle Duncan | Director | A | +65,000 deriv. | — |
| 2026-03-02 | Bart Friedman | Director | A | +65,000 deriv. | — |
| 2026-03-02 | Jeffrey A Rona | CBFO | MIXED | +59,584 | −$12.38K |
| 2026-03-02 | Margaret A. Alexander | President and CEO | Sell | −11,656 | −$16.90K |
| 2026-03-02 | Karen Bernstein | Director | A | +65,000 deriv. | — |
| 2026-03-02 | Kevin Joseph Fitzgerald | Director | A | +65,000 deriv. | — |
| 2026-01-05 | Margaret A. Alexander | President and CEO | A | +890,000 deriv. | — |
| 2025-12-18 | Jeremy M Levin | CEO | C | +71,000 | — |
| 2025-12-09 | TAKEDA PHARMACEUTICAL CO LTD | 10%+ Owner | C | +2,500,000 | — |
| 2025-06-18 | Karen Bernstein | Director | A | +45,000 deriv. | — |
| 2025-06-18 | Bart Friedman | Director | A | +45,000 deriv. | — |
| 2025-06-18 | Kevin Joseph Fitzgerald | Director | A | +45,000 deriv. | — |
| 2025-06-18 | Barbara Gayle Duncan | Director | A | +45,000 deriv. | — |
| 2025-03-04 | Stelios Papadopoulos | Director | A | +90,000 deriv. | — |
| 2025-02-28 | Jeffrey A Rona | CBFO | Sell | −3,902 | −$2.19K |
| 2025-02-28 | Margaret A. Alexander | President and COO | Sell | −5,279 | −$2.96K |
| 2025-02-24 | Margaret A. Alexander | President and COO | A | +43,750 | — |
| 2025-02-24 | Jeffrey A Rona | CBFO | A | +43,750 | — |
| 2025-02-24 | Jeremy M Levin | CEO | A | +1,650,000 deriv. | — |
| 2025-01-29 | Margaret A. Alexander | President and COO | Buy | +6,810 | +$4.97K |
| 2024-12-16 | Karen Bernstein | Director | A | +90,000 deriv. | — |
| 2024-12-16 | Kevin Joseph Fitzgerald | Director | A | +90,000 deriv. | — |
| 2024-12-16 | Barbara Gayle Duncan | Director | A | +90,000 deriv. | — |
| 2024-12-16 | Bart Friedman | Director | A | +90,000 deriv. | — |
| 2024-09-11 | Margaret A. Alexander | President and COO | A | +140,000 deriv. | — |
| 2024-08-01 | Jeffrey A Rona | CBFO | A | +315,000 deriv. | — |
| 2024-03-20 | Jeremy M Levin | CEO | Buy | +18,248 | +$50.36K |
| 2024-02-26 | Karen Bernstein | Director | A | +30,000 deriv. | — |
| 2024-02-26 | Robert Michael Poole | Director | A | +30,000 deriv. | — |
| 2024-02-26 | Barbara Gayle Duncan | Director | A | +30,000 deriv. | — |
| 2024-02-26 | Jeffrey A Rona | CBFO | A | +28,125 | — |
| 2024-02-26 | Jeremy M Levin | CEO | A | +700,000 deriv. | — |
| 2024-02-26 | Jason Tardio | Chief Operating Officer | A | +28,125 | — |
| 2024-02-26 | Thomas Michael Perone | General Counsel, Secretary | A | +28,125 | — |
| 2024-02-26 | Kevin Joseph Fitzgerald | Director | A | +30,000 deriv. | — |
| 2024-02-26 | Bart Friedman | Director | A | +30,000 deriv. | — |
| 2024-02-14 | Jeremy M Levin | CEO | G | −465,116 | — |
| 2023-12-06 | Jeremy M Levin | CEO | G | −1,146,550 | — |
| 2023-02-27 | Karen Bernstein | Director | A | +15,000 deriv. | — |
| 2023-02-27 | Jeremy M Levin | CEO | A | +600,000 deriv. | — |
| 2023-02-27 | Kevin Joseph Fitzgerald | Director | A | +15,000 deriv. | — |
| 2023-02-27 | Robert Michael Poole | Director | A | +15,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTD | 10%+ Owner | 8,781,996 | $22.31M |
| Jeremy M Levin | Executive Chairman | 3,770,509 | $9.58M |
| Stelios Papadopoulos | Director | 217,578 | $552.65K |
| Charles Ross Carter | Chief Financial Officer | 94,375 | $239.71K |
| Jeffrey A Rona | CBFO | 88,188 | $224.00K |
| Margaret A. Alexander | President and CEO | 61,750 | $156.84K |
| Karen Bernstein | Director | 20,000 | $50.80K |
| Kevin Joseph Fitzgerald | Director | 17,578 | $44.65K |
| Bart Friedman | Director | 8,789 | $22.32K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OVID quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.